<div class="flex max-w-full flex-col gap-4 grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1" dir="auto" tabindex="0" data-message-author-role="assistant" data-message-id="d5cfd2d9-7ea3-4080-96cb-0046f7b66ed5" data-message-model-slug="gpt-5-5" data-turn-start-message="true">
<div class="flex w-full flex-col gap-1 empty:hidden">
<div class="markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling">
<h2 data-section-id="kc7rwb" data-start="0" data-end="26"><strong>Uterine Fibroids Market</strong></h2>
<p data-start="28" data-end="512">The US <a href="https://www.delveinsight.com/report-store/uterine-fibroids-market"><strong>uterine fibroids market</strong></a> is witnessing gradual growth due to the rising prevalence of the disease, delayed pregnancies, and increasing adoption of minimally invasive treatment approaches. In 2025, the market size was estimated at nearly USD 980 million and is projected to grow at a CAGR of 1.9% during 2026&ndash;2036. Traditional therapies such as prescription analgesics and hormonal contraceptives continue to dominate the market, while oral GnRH antagonists are gaining traction.</p>
<ul data-start="514" data-end="781">
<li data-section-id="lax0tt" data-start="514" data-end="581">Prescription analgesics generated nearly USD 300 million in 2025.</li>
<li data-section-id="sy2ccy" data-start="582" data-end="640">MYFEMBREE/RYEQO generated around USD 45 million in 2025.</li>
<li data-section-id="g0fm8z" data-start="641" data-end="703">ORIAHNN contributed approximately USD 10 million in revenue.</li>
<li data-section-id="1g0wu4j" data-start="704" data-end="781">Advancements in imaging and diagnosis continue supporting market expansion.</li>
</ul>
<h2 data-section-id="12xwnis" data-start="783" data-end="815"><strong>Uterine Fibroids Epidemiology</strong></h2>
<p data-start="817" data-end="1208"><a href="https://www.delveinsight.com/report-store/uterine-fibroids-epidemiology-forecast"><strong>Uterine fibroids</strong></a> are among the most common benign gynecologic tumors affecting women of reproductive age in the United States. The epidemiology burden remains substantial due to increasing maternal age and improved disease recognition through advanced diagnostic techniques such as <a href="https://www.delveinsight.com/report-store/ultrasound-devices-market"><strong>ultrasound</strong></a> and <a href="https://www.delveinsight.com/report-store/magnetic-resonance-imaging-devices-market"><strong>MRI</strong></a>. Disease prevalence rises significantly with age, especially among women aged 40&ndash;49 years.</p>
<ul data-start="1210" data-end="1522">
<li data-section-id="lju4b" data-start="1210" data-end="1275">Total prevalent cases in the US in 2025 were nearly 27 million.</li>
<li data-section-id="15us5yo" data-start="1276" data-end="1342">Diagnosed prevalent cases accounted for approximately 8 million.</li>
<li data-section-id="rtcinn" data-start="1343" data-end="1392">Treated cases reached around 4 million in 2025.</li>
<li data-section-id="bxzd7" data-start="1393" data-end="1456">Women aged 40&ndash;49 years represented nearly 38% of total cases.</li>
<li data-section-id="zmnpcu" data-start="1457" data-end="1522">The 15&ndash;29 years age group accounted for only about 4% of cases.</li>
</ul>
<h2 data-section-id="1wsk83h" data-start="1524" data-end="1552"><strong>Uterine Fibroids Pipeline</strong></h2>
<p data-start="1554" data-end="1997">The <a href="https://www.delveinsight.com/report-store/uterine-fibroids-pipeline-insight"><strong>uterine fibroids pipeline</strong></a> remains relatively limited, with few late-stage emerging therapies currently available in the US market. Existing treatment development primarily focuses on symptom management, heavy menstrual bleeding control, and fertility preservation. Pharmaceutical companies are increasingly exploring oral GnRH antagonist therapies to provide safer and long-term treatment alternatives compared with surgical interventions.</p>
<ul data-start="1999" data-end="2483" data-is-last-node="" data-is-only-node="">
<li data-section-id="79axdl" data-start="1999" data-end="2119">Approved therapies include ORIAHNN by <span class="whitespace-normal">AbbVie</span> and <span class="whitespace-normal">Neurocrine Biosciences</span>.</li>
<li data-section-id="twy6fe" data-start="2120" data-end="2191">MYFEMBREE/RYEQO is marketed by <span class="whitespace-normal">Sumitomo Pharma</span>.</li>
<li data-section-id="1i4t6ea" data-start="2192" data-end="2305">Key companies involved include <span class="whitespace-normal">Pfizer</span> and <span class="whitespace-normal">Myovant Sciences</span>.</li>
<li data-section-id="11vvtmq" data-start="2306" data-end="2399">Major unmet needs include fertility-preserving therapies and nonhormonal treatment options.</li>
<li data-section-id="sqg197" data-start="2400" data-end="2483" data-is-last-node="">Lack of active late-stage pipeline candidates remains a major industry challenge.</li>
</ul>
</div>
</div>
</div>
</div>
<div class="mt-3 w-full empty:hidden">
<div class="text-center">
<div class="mx-auto">
<div>
<div class="inline-flex rounded-xl border border-gray-100 dark:border-gray-700">
<div class="me-12 flex items-center px-4 py-3 text-start">&nbsp;</div>
</div>
</div>
</div>
</div>
</div>

Uterine Fibroids Market

Uterine Fibroids Market Infographic

Uterine Fibroids Market Thumbnail

Uterine Fibroids Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape